Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Olivier De Henau, Matthew Rausch, David Winkler, Luis Felipe Campesato, Cailian Liu, Daniel Hirschhorn Cymerman, Sadna Budhu, Arnab Ghosh, Melissa Pink, Jeremy Tchaicha, Mark Douglas, Thomas Tibbitts, Sujata Sharma, Jennifer Proctor, Nicole Kosmider, Kerry White, Howard Stern, John Soglia, Julian Adams, Vito J. Palombella, Karen McGovern, Jeffery L. Kutok, Jedd D. Wolchok () and Taha Merghoub ()
Additional contact information
Olivier De Henau: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Matthew Rausch: Infinity Pharmaceuticals, Inc.
David Winkler: Infinity Pharmaceuticals, Inc.
Luis Felipe Campesato: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Cailian Liu: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Daniel Hirschhorn Cymerman: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Sadna Budhu: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Arnab Ghosh: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Melissa Pink: Infinity Pharmaceuticals, Inc.
Jeremy Tchaicha: Infinity Pharmaceuticals, Inc.
Mark Douglas: Infinity Pharmaceuticals, Inc.
Thomas Tibbitts: Infinity Pharmaceuticals, Inc.
Sujata Sharma: Infinity Pharmaceuticals, Inc.
Jennifer Proctor: Infinity Pharmaceuticals, Inc.
Nicole Kosmider: Infinity Pharmaceuticals, Inc.
Kerry White: Infinity Pharmaceuticals, Inc.
Howard Stern: Infinity Pharmaceuticals, Inc.
John Soglia: Infinity Pharmaceuticals, Inc.
Julian Adams: Infinity Pharmaceuticals, Inc.
Vito J. Palombella: Infinity Pharmaceuticals, Inc.
Karen McGovern: Infinity Pharmaceuticals, Inc.
Jeffery L. Kutok: Infinity Pharmaceuticals, Inc.
Jedd D. Wolchok: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
Taha Merghoub: Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory

Nature, 2016, vol. 539, issue 7629, 443-447

Abstract: Targeting tumour-infiltrating suppressive myeloid cells with a selective PI3Kγ inhibitor overcomes resistance to checkpoint blockade therapy in various mouse myeloid-rich tumour models.

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
https://www.nature.com/articles/nature20554 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:539:y:2016:i:7629:d:10.1038_nature20554

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature20554

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().